Management Board ǀ Apogenix

Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.

Board of Directors

Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition

Governance in a Changing Environment

Gene expression profiles in genome instability-based classes of colorectal cancer, BMC Cancer

Contact Request ǀ Apogenix

Board Evaluation HopgoodGanim Lawyers

The Perfect Corporate Board: A Handbook for Mastering the Unique Challenges of Small-Cap Companies: 9780071799546: Epstein, Adam: Books

Best Board Management Software 2024 - Reviews on 81+ Tools

Clinical Trials in MDS ǀ Apogenix